ArticleJournal of veterinary internal medicine2026
Renoprotective effects of curcumin in cats with chronic kidney disease.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) in cats is characterized by oxidative stress, inflammation, and apoptosis. Curcumin has shown renoprotective effects in experimental models, but clinical evidence in cats with CKD remains limited. HYPOTHESIS/
objectivesEvaluate whether PO curcumin supplementation (80 mg/cat/day), administered with standard treatment, favorably modulates renal, oxidative, inflammatory, and apoptotic biomarkers in cats with International Renal Interest Society (IRIS) stage 3 CKD. ANIMALS: Sixteen client-owned cats with IRIS stage 3 CKD.
methodsProspective, randomized trial. Cats were allocated to medical treatment alone (MT; n = 8) or medical treatment plus curcumin (MT + C; n = 8). Curcumin was administered PO at 80 mg/cat/day in 2 divided doses for 60 days.
resultsBaseline renal biomarkers did not differ between groups. The primary outcome, serum symmetric dimethylarginine (SDMA) concentration, was significantly lower in the MT + C group than in the MT group on days 30, 45, and 60 (P < .01). Urinary protein-to-creatinine ratio decreased over time in the MT + C group and was lower than in the MT group at later time points. Total antioxidant status increased, whereas total oxidant status decreased in the MT + C group, with a significant between-group difference in total oxidant status on day 45. Findings for nuclear factor kappa B and caspase-3 were also consistent with decreased inflammatory and apoptotic activity in curcumin-treated cats. CONCLUSIONS AND CLINICAL IMPORTANCE: Curcumin supplementation was associated with improvement in SDMA and favorable changes in mechanistic biomarkers in cats with IRIS stage 3 CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.